In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Yumanity Therapeutics closes $45mm Series A round

Executive Summary

Yumanity Therapeutics (neurodegenerative disease therapeutics) raised $45mm in its Series A round led by Fidelity Management & Research Co. Other investors included Redmile Group (a participant in its 2015 seed funding), Alexandria Venture Investments, Biogen Inc., Sanofi-Genzyme BioVentures, and Dolby Family Ventures. One executive from Biogen and one from Alexandria joined the board.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies